Success Metrics

Clinical Success Rate
100.0%

Based on 5 completed trials

Completion Rate
100%(5/5)
Active Trials
6(38%)
Results Posted
120%(6 trials)

Phase Distribution

Ph phase_3
5
31%
Ph phase_2
7
44%
Ph phase_4
1
6%
Ph phase_1
2
13%

Phase Distribution

2

Early Stage

7

Mid Stage

6

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
2(13.3%)
Phase 2Efficacy & side effects
7(46.7%)
Phase 3Large-scale testing
5(33.3%)
Phase 4Post-market surveillance
1(6.7%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

5 of 6 finished

Non-Completion Rate

16.7%

1 ended early

Currently Active

6

trials recruiting

Total Trials

16

all time

Status Distribution
Active(6)
Completed(5)
Terminated(1)
Other(4)

Detailed Status

Completed5
unknown3
Active, not recruiting3
Recruiting3
Withdrawn1
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
16
Active
6
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Phase 12 (13.3%)
Phase 27 (46.7%)
Phase 35 (33.3%)
Phase 41 (6.7%)

Trials by Status

unknown319%
withdrawn16%
active_not_recruiting319%
suspended16%
recruiting319%
completed531%

Recent Activity

Clinical Trials (16)

Showing 16 of 16 trials
NCT02883049Phase 3

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations

Active Not Recruiting
NCT02112916Phase 3

Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

Active Not Recruiting
NCT05761171Phase 2

A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leukemia

Active Not Recruiting
NCT06247787Phase 1

A Study to Find the Highest Dose of Imetelstat in Combination With Fludarabine and Cytarabine for Patients With AML, MDS or JMML That Has Come Back or Does Not Respond to Therapy

Recruiting
NCT03401398Phase 3

Stress Hydrocortisone In Pediatric Septic Shock

Recruiting
NCT04546399Phase 2

A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

Recruiting
NCT00476190Phase 2

ALL Adult Consortium Trial: Adult ALL Trial

Completed
NCT02828358Phase 2

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Completed
NCT05320380Phase 1

A Study of the Drug IMGN632 in Children With Leukemia That Has Come Back After Treatment or is Difficult to Treat

Withdrawn
NCT00720109Phase 2

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Completed
NCT04301479Phase 3

Low Dose Corticosteroid Infusion in Vasoplegia After Cardiac Surgery (CORTIVAS-CS)

Unknown
NCT03110198Phase 4

Mesalazine With Hydrocortisone Sodium Succinate Enema for 4-Week Treatment in Patients With Ulcerative Colitis

Unknown
NCT00057811Phase 2

Rituximab, Rasburicase, and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Advanced B-Cell Leukemia or Lymphoma

Completed
NCT01005758Phase 2

Combination Chemotherapy in Treating Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

Unknown
NCT01608945

Prospective Randomized Study of Glucocorticoids in the Impact of the Liver Function and the Prognosis After Hepatectomy of HCC

Suspended
NCT00147004Phase 3

Corticosteroid Therapy of Septic Shock - Corticus

Completed

All 16 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
16